期刊
JOURNAL OF CONTROLLED RELEASE
卷 156, 期 3, 页码 297-306出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2011.07.032
关键词
Ultrasound contrast agents; Microbubble; Targeted drug delivery; Molecular imaging; Therapeutic ultrasound
资金
- NCI NIH HHS [R01 CA112356, R01 CA112356-06, R01 CA134659, P30 CA093373, R01 CA134659-03, R01 CA103828] Funding Source: Medline
- NIBIB NIH HHS [T32 EB003827, T32 EB003827-09] Funding Source: Medline
Contrast agent-enhanced ultrasound can facilitate personalized therapeutic strategies by providing the technology to measure local blood flow rate, to selectively image receptors on the vascular endothelium, and to enhance localized drug delivery. Ultrasound contrast agents are micron-diameter encapsulated bubbles that circulate within the vascular compartment and can be selectively imaged with ultrasound. Microbubble transport-based estimates of local blood flow can quantify changes resulting from anti-angiogenic therapies and facilitate differentiation of angiogenic mechanisms. Microbubbles that are conjugated with targeting ligands attach to endothelial surface receptors that are upregulated in disease, providing high signal-to-noise ratio images of pathological vasculature. In addition to imaging applications, microbubbles can be used to enhance localized gene and drug delivery, either by changing membrane and vascular permeability or by carrying and locally releasing cargo. Our goal in this review is to provide an overview of the use of contrastenhanced ultrasound methodologies in the design and evaluation of therapeutic strategies with emphases on quantitative blood flow mapping, molecular imaging, and enhanced drug delivery. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据